B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
نویسندگان
چکیده
منابع مشابه
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
B cells have paradoxical roles in autoimmunity, exerting both pathogenic and protective effects. Pathogenesis may be antibody independent, as B cell depletion therapy (BCDT) leads to amelioration of disease irrespective of autoantibody ablation. However, the mechanisms of pathogenesis are poorly understood. We demonstrate that BCDT alleviates central nervous system autoimmunity through ablation...
متن کاملB cell depletion in autoimmune disease
The CD20 cell marker appears early in the process of B cell development. In this review we focus on the results of attempts to utilize B cell depletion based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with autoimmune diseases. In 1997, rituximab was approved for the treatment of low-grade B cell non-Hodgkin's lymphoma. Fo...
متن کاملB cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice.
MRL/lpr mice develop a spontaneous systemic lupus erythematosus-like autoimmune syndrome due to a dysfunctional Fas receptor, with contributions from other less well-defined genetic loci. The removal of B cells by genetic manipulation not only prevents autoantibody formation, but it also results in substantially reduced T cell activation and kidney inflammation. To determine whether B cell depl...
متن کاملB cell depletion: a novel therapy for autoimmune diabetes?
Autoimmune diabetes is believed to be mediated primarily by T cells. However, B cells have been implicated in the pathogenesis of the disease in NOD mice. Although preclinical studies have been limited by the absence of anti-CD20 reagents that can induce B cell depletion in mice, a clinical trial using the B cell-depleting anti-CD20 monoclonal antibody rituximab (Rituxan) is underway in type 1 ...
متن کاملProspects for B-cell-targeted therapy in autoimmune disease.
Reasons for targeting B cells in autoimmune disease date back to the discovery of autoantibodies over 50 yr ago [1]. The idea became of practical interest when anti-B cell monoclonal antibodies were developed in the early 1990s [2, 3]. Fortuitously, at about the same time it became clear that B cells are not simply the subordinate foot soldiers of an immune response but may be as important as T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Experimental Medicine
سال: 2012
ISSN: 1540-9538,0022-1007
DOI: 10.1084/jem.20111675